PMCB vs TMO · $8.6M cap vs P/E 24, rev $44.56B
PharmaCyte Biotech Inc (PMCB) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
PMCB currently screens at market cap $8.6M. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the PMCB and TMO stock pages for the full models.
Not investment advice.